Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells

Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: Reappraisal of epidemiological, clinical, and pathological features

“…6,7 Tissue examination For conventional light microscopy, tissue specimens from the patients were bisected and fixed in 4% buffered formalin, embedded in paraffin wax, and stained with hematoxylin-eosin. Two 4-mm punch biopsy samples were obtained from each patient.…”

Toxic erythema of chemotherapy: A useful clinical term

“…2,3,[18][19][20][21][22][23][24][25][26][27][28] The latter is best exemplified by the designations ''eccrine squamous syringometaplasia,'' 19,26 ''epidermal dystrophy,'' 25 and ''epidermal dysmaturation,'' 29,30 terms that, while clearly apt and insightful, may not even be that familiar to dermatologists and are certainly foreign to hematologists and oncologists. We are recommending a new clinically descriptive term, toxic erythema of chemotherapy (TEC), in order to emphasize the overlapping features of the entities outlined in Table II and to provide a straightforward, easily understood clinical name that enhances communication and patient care.…”

“…34 In addition, intertriginous eruptions caused by chemotherapy can have evidence of epidermal dysmaturation 23 and eccrine squamous syringometaplasia. 26 It is also noteworthy that the inciting chemotherapeutic agents for each of these entities also exhibit significant overlap.…”

“…There may be scattered papules at the periphery of the plaques, and papules and plaques can also involve the head and neck (especially in chemotherapy-associated neutrophilic eccrine hidradenitis) and the trunk 1 and extremities 26 (ie, have a more generalized distribution). 19,26 A delayed onset of up to 2 to 10 months 52 can be seen in patients who are receiving lower-dose, continuous intravenous infusions (eg, 5-fluorouracil) or oral agents that mimic prolonged infusions.…”

Coexistence of Eccrine Squamous Syringometaplasia and Graft-Versus-Host Disease in a Patient with Secondary Myelodysplastic Syndrome

“…Chemotherapy-induced ESS could be explained by damage to the eccrine ducts, by exces sive sweat gland production and/or drug concentration in this secretion. Moreover, other factors such as local irritation or friction may be implicated (1,4). ESS does not require a specific treatment and it is not a prognosis factor; both depend on the underlying disease.…”